Paid Clinical Trials in High Point, NC

Paid Clinical Trials in High Point, NC

Find paid studies that are recruiting healthy participants in High Point, NC. Filter by distance, duration, and inclusion criteria to find clinical trials that pay well for your time.

Popular Trials

Michael Bask Gill, B Sc preview

Michael Bask Gill, B Sc

Last Reviewed: March 19th, 2025

Birmingham, Alabama

Placebo +1 More for Eosinophilic Esophagitis

Recruiting0 awardsPhase 2
Chapel Hill, North Carolina
This trial is testing whether a pill called etrasimod can safely and effectively treat adults with active eosinophilic esophagitis, a condition where the esophagus gets inflamed due to certain white blood cells. Etrasimod aims to reduce this inflammation by calming down the immune system.
Artesia, California

Ophthalmic Solution

DE-126 Ophthalmic Solution for Open-Angle Glaucoma

Recruiting2 awardsPhase 2
High Point, North Carolina
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field loss. This study is being conducted to determine how well DE-126 ophthalmic solution works (efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate the safety and efficacy of four (4) concentrations of DE-126, when compared with latanoprost (0.005%) eye drops in patients with primary open-angle glaucoma or ocular hypertension. The IOP will be measured at 3 different times throughout the day, over 6 total visits during a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop taking current eye drops to lower IOP). Safety assessments will be done throughout the study, including ocular signs and symptoms, vital signs, and clinical laboratory tests. While the most important time-point to measure IOP in this study and evaluate efficacy will be at the final study visit (month 3), IOP values will also be evaluated at other visits throughout the 3-month treatment period.
Birmingham, Alabama

Chemotherapy

Haploidentical Bone Marrow Transplant for Sickle Cell Disease

Recruiting1 awardPhase 2
Durham, North Carolina
This trial tests a special type of bone marrow transplant for children and adults with severe sickle cell disease. It uses medications to prepare the body and a donor to replace defective bone marrow. The goal is to improve survival without major complications. Bone marrow transplantation is currently the only curative therapy for sickle cell disease, but it is limited by side effects and finding suitable donors.
Mobile, Alabama

Monoclonal Antibodies

Adalimumab +1 More for Ulcerative Colitis

Recruiting2 awardsPhase 3
Chapel Hill, North Carolina
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
Glendale, Arizona

Anticholinergic/Beta2-agonist Combination

Glycopyrrolate/Formoterol Fumarate MDI for Chronic Obstructive Pulmonary Disease

Recruiting2 awardsPhase 2
Rock Hill, South Carolina
The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD
Birmingham, Alabama

Immunomodulator

Fingolimod +1 More for Multiple Sclerosis

Recruiting1 award5 criteria
Augusta, Georgia
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.

Popular Filters

Age 65+
Phase 3
< 50 mile distance
No Placebo

Phase 3 Trials

Birmingham, Alabama

Prostacyclin Analogue

Oral treprostinil for Pulmonary Hypertension

Recruiting2 awardsPhase 3
Pinehurst, North Carolina
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects took the initial dose of study drug at the study site on the day of randomization. Subjects returned to the study site for visits scheduled at Weeks 6, 12, 18, and 24. The duration of study participation was approximately 28 weeks from Screening until study completion (includes a 30-day Screening Phase and 24-week Treatment Phase). The study was discontinued by the Sponsor on 14 October 2019 due to slow enrollment. As only a small portion of the anticipated total subjects had been enrolled, with many terminating early due to the study termination, there was a limited ability to explore the effect of oral treprostinil in this indication in this study.
Phoenix, Arizona

Idalopirdine for Alzheimer's Disease

Recruiting1 awardPhase 3
Winston-Salem, North Carolina
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
Chandler, Arizona

CDK4/6 Inhibitor

LEE011 +1 More for Breast Cancer

Recruiting1 awardPhase 3
Durham, North Carolina
This trialtests a new medical treatment to see if it works better than a placebo.
Fountain Valley, California

Corticosteroid

Dexamethasone +2 More for Multiple Myeloma

Recruiting4 awardsPhase 3
Winston Salem, North Carolina
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Phoenix, Arizona

RVL-1201 for Drooping of the Neck, Mid-face and/or Jowl

Recruiting1 awardPhase 3
High Point, North Carolina
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Duarte, California

Radioactive Diagnostic Imaging Agent

99mTc-MIP-1404 Injection for Prostate Cancer

Recruiting2 awardsPhase 3
Concord, North Carolina
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason Score of ≤ 3+4 severity who are candidates for active surveillance and are undergoing voluntary radical prostatectomy (RP) \[Cohort A\] or routine prostate biopsy \[Cohort B\]. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 SPECT/CT imaging to correctly identify subjects with previously unknown clinically significant prostate cancer.

Trials With No Placebo

Basking Ridge, New Jersey

Hormone Therapy

Tinengotinib + Standard Treatments for Prostate Cancer

Recruiting1 awardPhase 1 & 2
Durham, North Carolina
This trial aims to determine if tinengotinib, when taken together with either abiraterone acetate and prednisone or enzalutamide, is a safe treatment with minimal
Duarte, California

Anti-tumor antibiotic

APL-5125 for Colorectal Cancer

Recruiting1 awardPhase 1 & 2
Durham, North Carolina
This trial will test the safety, side effects, and effectiveness of a drug called APL-5125 for treating advanced solid tumors, specifically focusing on colorectal cancer.
Homewood, Alabama

Hormone Therapy

Dimethyl Fumarate +3 More for Multiple Sclerosis

Recruiting1 award4 criteria
Raleigh, North Carolina
The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF). Secondary objectives of the study are: To evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with DMF, glatiramer acetate (GA), teriflunomide, or fingolimod both in the overall participant cohort and in a subset of participants who were naïve to disease-modifying therapy (DMT) and were diagnosed with multiple sclerosis (MS) within 3 years of starting the index therapy; To compare relapse activity, defined as annualized relapse rate (ARR), among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare MS-related hospitalizations among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare intravenous corticosteroid use among participants treated with DMF, GA, teriflunomide, or fingolimod.
Fountain Valley, California

Corticosteroid

Dexamethasone +2 More for Multiple Myeloma

Recruiting4 awardsPhase 3
Winston Salem, North Carolina
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Raleigh, North Carolina

Meal Preparation

Central Kitchen for Healthy Eating

Recruiting1 award1 criteria
Raleigh, North Carolina
This trial will test a central kitchen that prepares and delivers meals to child care centers in rural Harnett County, North Carolina. The goal is to improve meal quality and reduce the workload on child care providers. Researchers will measure the children's fruit and vegetable intake using a device that checks nutrient levels in their skin.
San Francisco, California

Behavioral Intervention

IOK Therapy for PTSD

Recruiting1 award7 criteria
Durham, North Carolina
This trial is testing whether a new treatment called Impact of Killing (IOK) is more effective than present-centered therapy (PCT) for treating post-traumatic stress disorder (PTSD) in veterans.

View More Related Trials

Aripiprazole

Radiation Therapy

Placebo +1 More

Quit on the Go App

Placebo +1 More

BOS-589

Protego DF4 Right Ventricular Lead

Placebo

Linaclotide

Tipranavir

Etoposide +5 More

Cisplatin +3 More

AMG 193 +1 More

Placebo +1 More

Placebo

SGN-2FF

Zoledronic Acid

Sunitinib Malate Continuous Daily Dosing +1 More

Aldesleukin

Posoleucel (ALVR105,Viralym-M)

Rifaximin SSD

Guselkumab +2 More

Placebo +2 More

Cemiplimab REGN2810 +1 More

Saxagliptin

Deoxycholic Acid Injection

Fluticasone Furoate +1 More

None

Paclitaxel +2 More

NOV03

Zifibancimig

Interactive Technology Enhanced Coaching (ITEC)

Tx360

Filgotinib

Faricimab

Topiramate +1 More

Laquinimod

Tamoxifen +1 More

Docetaxel +1 More

Personalized Diet Information

Lete-Cel

Axicabtagene Ciloleucel

Placebo +1 More

Gemcitabine Hydrochloride

Venetoclax +13 More

Enzalutamide +1 More

Macitentan

Etoposide +8 More

RE104 for Injection

ADT +1 More

Xanomeline and Trospium Chloride Capsules

Zanubrutinib

Atezolizumab +3 More

Daclatasvir +1 More

Methylphenidate

Insulin

Duloxetine

Brachytherapy

Placebo +1 More

ELU001

ARDA software application

CG0070

GWP42003-P

Laboratory Biomarker Analysis

Laboratory Biomarker Analysis

Bevacizumab +2 More

Placebo +1 More

Dexamethasone +1 More

Ligelizumab

Epetraborole

Placebos +3 More

Lubiprostone

Dabrafenib +2 More

Placebo +1 More

Carboplatin +2 More

ziv-aflibercept

GSK221149A

Zidovudine (AZT)

View more paid studies high point

See more medical studies focusing on paid studies high point

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top